fda vertex pharmaceuticals

Vertex Pharmaceuticals Shares Gain

Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

MarketWatch · 3h

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

The Wall Street Journal on MSN · 12h

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.

Vertex Stock Jumps After Non-Opioid Painkiller Gets FDA Approval

Shares of Vertex Pharmaceuticals rose 8% in off-hours trading after the pharmaceutical company won U.S. approval for the [first new non-opioid painkiller in decades]( ...

Vertex Pharmaceuticals price target raised to $435 from $418 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $435 from $418 and keeps an Equal Weight rating ...

FDA green lights new painkiller

The new drug type targets pathways in the peripheral nervous system before pain signals reach the brain, potentially lowering ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Vertex Pharmaceuticals Shares Gain

Trending now